Stage IIIB Cutaneous Melanoma AJCC v7 Recruiting Phase 2 Trials for Regramostim (DB05386)

IndicationStatusPhase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02965716Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTreatment